Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2006

01-12-2006 | Clinical Trial

Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

Authors: David Cella, Lesley Fallowfield, Peter Barker, Jack Cuzick, Gershon Locker, Anthony Howell, On behalf of the ATAC Trialistsȁ9 Group

Published in: Breast Cancer Research and Treatment | Issue 3/2006

Login to get access
Metadata
Title
Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer
Authors
David Cella
Lesley Fallowfield
Peter Barker
Jack Cuzick
Gershon Locker
Anthony Howell
On behalf of the ATAC Trialistsȁ9 Group
Publication date
01-12-2006
Published in
Breast Cancer Research and Treatment / Issue 3/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9260-6

Other articles of this Issue 3/2006

Breast Cancer Research and Treatment 3/2006 Go to the issue

Epidemiology

Early self-reported impairments in arm functioning of primary breast cancer patients predict late side effects of axillary lymph node dissection: results from a population-based cohort study

Preclinical Study

Direct-to-patient BRCA1 testing: the Twoj Styl experience

Clinical Trial

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy

Original report

Variation in false-positive rates of mammography reading among 1067 radiologists: a population-based assessment

Original Paper

Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806

Letter to the Editor

A high risk of occurrence of sporadic breast cancer in individuals with the 104NN polymorphism of the COL18A1 gene
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits